Sanofi

bluebird bio, a pioneer in gene therapies for severe genetic diseases, has appointed three new executives to strengthen its leadership team as the company focuses on commercial execution.

ESTEVE has entered into an agreement with Sanofi to acquire Caprelsa® (vandetanib) rights in more than 50 countries for treating aggressive and symptomatic medullary thyroid cancer in adults and children above 5 years of age.

Vor Bio acquired exclusive global rights (excluding Greater China) to develop and commercialize telitacicept, a dual-target fusion protein approved in China for multiple autoimmune diseases including generalized myasthenia gravis.

The newly appointed Advisory Committee on Immunization Practices (ACIP) voted 5-1 to recommend thimerosal-free influenza vaccines for all age groups, despite the preservative being present in only 6% of U.S. flu vaccines.

MIRA Pharmaceuticals announced new in vitro preclinical data from Eurofins demonstrating SKNY-1's potential as a first-in-class oral therapy for obesity and nicotine addiction without central nervous system side effects.

Sanofi has selected Kymera's KT-485, a next-generation oral IRAK4 degrader, to advance into Phase 1 clinical testing next year for immuno-inflammatory diseases.

Sanofi has committed up to $25 million in strategic investment to Adagene, extending the biotech's cash runway into 2027 and supporting clinical development of its lead SAFEbody candidate muzastotug.

Sanofi has licensed gusacitinib, an oral dual JAK/SYK inhibitor, from Formation Bio's subsidiary Libertas Bio in a deal worth up to €545 million including upfront payments, milestones, and low to mid-teen royalties.

Tharimmune announced key leadership changes with Sireesh Appajosyula becoming CEO and Vincent LoPriore appointed Executive Chairman in June 2025.

UCB plans to invest $5 billion in a new state-of-the-art biologics manufacturing facility in the United States, creating 300 permanent high-skilled jobs and over 500 construction positions.